Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568555 · ClinicalTrials.gov registry record · NA
Effects of Low Dose Naltrexone in Fibromyalgia
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
NCT00568555: Completed NA study, sponsored by Stanford University.
NCT00568555 is a NA study that has completed, run by Stanford University. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568555, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
Study Summary
Low Dose Naltrexone (LDN) has been reported anecdotally to reduce the symptoms of Fibromyalgia, a Chronic Multisystem Illness. The drug may work by regulating natural pain-reducing systems. In this study, we will administer both LDN and placebo to a small group of individuals with Fibromyalgia and Gulf War Syndrome, both Chronic Multisymptom Illnesses, to assess the drug's efficacy in treating the condition.
Interventions
- DRUG Low Dose Naltrexone
- DRUG Placebo - sugar pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568555
The ClinicalTrials.gov registry entry for NCT00568555 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Low Dose Naltrexone is the first listed.
NCT00568555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00568555 about?
NCT00568555 is a clinical study titled "Effects of Low Dose Naltrexone in Fibromyalgia". Low Dose Naltrexone (LDN) has been reported anecdotally to reduce the symptoms of Fibromyalgia, a Chronic Multisystem Illness. The drug may work by regulating natural pain-reducing systems. In this study, we will administer both LDN and placebo to a small group of individuals with Fibromyalgia and G...
What is the current status of trial NCT00568555?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2007-06. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00568555?
The interventions under investigation include: Low Dose Naltrexone (DRUG), Placebo - sugar pill (DRUG).
Who is sponsoring clinical trial NCT00568555?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.